How do you rank Intellia, Beam, Crispr Therapeutics and Invitae? I explain my ranking, You decide.
How do you rank Intellia, Beam, Crispr Therapeutics and Invitae? I explain my ranking, You decide.
|
Loading...
Lütfen bekleyiniz...
Type
Size

İlgili Videolar

How do you rank Intellia, Beam, Crispr Therapeutics and Invitae? I explain my ranking, You decide.

How do you rank Intellia, Beam, Crispr Therapeutics and Invitae? I explain my ranking, You decide.

|
BEAM Stock (Beam Therapeutics) brings CRISPR to the new level!

BEAM Stock (Beam Therapeutics) brings CRISPR to the new level!

|
Tessera Therapeutics: Will It Challenge Intellia, CRISPR, and Beam in Gene Editing?

Tessera Therapeutics: Will It Challenge Intellia, CRISPR, and Beam in Gene Editing?

|
Intellia and the #NewEraOfMedicine (in vivo CRISPR)

Intellia and the #NewEraOfMedicine (in vivo CRISPR)

|
The Beam Therapeutics Story

The Beam Therapeutics Story

|
BEAM Potential is Huge

BEAM Potential is Huge

|
Intellia Tx (NTLA Stock) NTLA-2002 HOME-RUN Data - Here's what to know!

Intellia Tx (NTLA Stock) NTLA-2002 HOME-RUN Data - Here's what to know!

|
Intellia Therapeutics

Intellia Therapeutics

|
Are we being impatient with Beam Therapeutics? Here I discuss some known hurdles to therapies.

Are we being impatient with Beam Therapeutics? Here I discuss some known hurdles to therapies.

|
CRISPR Rankings

CRISPR Rankings

|
CRISPR Therapeutics vs Competitors: Advantages & Opportunities for Gene Editing in treating SCD/TDT

CRISPR Therapeutics vs Competitors: Advantages & Opportunities for Gene Editing in treating SCD/TDT

|
Intellia Therapeutics Overview

Intellia Therapeutics Overview

|
FDA Explains Reasons on BEAM-201

FDA Explains Reasons on BEAM-201

|
BEAM-101 Moves Forward

BEAM-101 Moves Forward

|
$NTLA Base Editors Versus $BEAM Base Editors. (Ep. 222)

$NTLA Base Editors Versus $BEAM Base Editors. (Ep. 222)

|
NTLA Stock News: Latest updates on the company

NTLA Stock News: Latest updates on the company

|
Are CRSP stock and Beam stock worth this much?

Are CRSP stock and Beam stock worth this much?

|
A Bullish case for Beam Therapeutics

A Bullish case for Beam Therapeutics

|
Year End Review - Beam Therapeutics - Two Bright Spots into 2023

Year End Review - Beam Therapeutics - Two Bright Spots into 2023

|
Denali's Proposed Novel Approach to Transporting Biotherapeutics Across the Blood-Brain Barrier

Denali's Proposed Novel Approach to Transporting Biotherapeutics Across the Blood-Brain Barrier

|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa